Cargando…

Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease

INTRODUCTION: End‐stage renal disease (ESRD) is associated with increased infectious susceptibility and with reduced vaccine responses consistent with compromised humoral immunity. Whether the compromised humoral immunity is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Assing, Kristian, Nielsen, Christian, Jakobsen, Marianne, Scholze, Alexandra, Nybo, Mads, Soerensen, Grete, Mortensen, Sussie, Vejen, Knud, Barington, Torben, Bistrup, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879468/
https://www.ncbi.nlm.nih.gov/pubmed/27957330
http://dx.doi.org/10.1002/iid3.108
_version_ 1782433676415467520
author Assing, Kristian
Nielsen, Christian
Jakobsen, Marianne
Scholze, Alexandra
Nybo, Mads
Soerensen, Grete
Mortensen, Sussie
Vejen, Knud
Barington, Torben
Bistrup, Claus
author_facet Assing, Kristian
Nielsen, Christian
Jakobsen, Marianne
Scholze, Alexandra
Nybo, Mads
Soerensen, Grete
Mortensen, Sussie
Vejen, Knud
Barington, Torben
Bistrup, Claus
author_sort Assing, Kristian
collection PubMed
description INTRODUCTION: End‐stage renal disease (ESRD) is associated with increased infectious susceptibility and with reduced vaccine responses consistent with compromised humoral immunity. Whether the compromised humoral immunity is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or altered germinal center (GC) dynamics is not known. The GC‐derived chemokine CXCL13 as well as peripheral T follicular helper cells (pTFH) reflect GC dynamics, but have, similar to SHM, never been characterized in relation to ESRD. METHODS: Serum CXCL 13 was determined by ELISA. PTFH were flow‐cytometrically defined as CD4(+) CD45RA(−) CCR7(+) CXCR5(+) lymphocytes. Apoptotic lymphocyte subsets were in addition annexin V(+). SHM was determined, by next‐generation sequencing and bioinformatics, as nucleotide mutations within the IgG V(H) (comprising the important antigen‐binding domains of IgG, CDR1, and CDR2). RESULTS: Elevated CXCL13 levels characterized ESRD (n = 19; [median] 90 pg/ml, P < 0.01) (controls, n = 18; 62 pg/ml). ESRD pTFH frequencies (n = 19; 11.6% [of CD4(+) memory T cells], P < 0.02*, *Bonferroni corrected) (controls, n = 22; 14.9%) and concentrations (n = 19; 0.03 × 10(9)/L, P < 0.02*) (controls, n = 22; 0.07 × 10(9)/L) were reduced. ESRD pTFH were more apoptotic (n = 9; 25.7%, P = 0.04*) (controls, n = 10; 15.9%). SHM did not discriminate between ESRD (n = 10; 7.4%, P = 0.21) and controls (n = 10; 8.4%). CONCLUSIONS: Elevated CXCL13 levels, reduced pTFH levels, and increased pTFH apoptosis suggest that perturbed GC dynamics, and not reduced antibody diversity, underlie the diminished vaccine responses and the compromised humoral immunity in ESRD. However, largely preserved SHM provides a rationale for pursuing vaccination in relation to ESRD.
format Online
Article
Text
id pubmed-4879468
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48794682016-12-12 Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease Assing, Kristian Nielsen, Christian Jakobsen, Marianne Scholze, Alexandra Nybo, Mads Soerensen, Grete Mortensen, Sussie Vejen, Knud Barington, Torben Bistrup, Claus Immun Inflamm Dis Original Research INTRODUCTION: End‐stage renal disease (ESRD) is associated with increased infectious susceptibility and with reduced vaccine responses consistent with compromised humoral immunity. Whether the compromised humoral immunity is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or altered germinal center (GC) dynamics is not known. The GC‐derived chemokine CXCL13 as well as peripheral T follicular helper cells (pTFH) reflect GC dynamics, but have, similar to SHM, never been characterized in relation to ESRD. METHODS: Serum CXCL 13 was determined by ELISA. PTFH were flow‐cytometrically defined as CD4(+) CD45RA(−) CCR7(+) CXCR5(+) lymphocytes. Apoptotic lymphocyte subsets were in addition annexin V(+). SHM was determined, by next‐generation sequencing and bioinformatics, as nucleotide mutations within the IgG V(H) (comprising the important antigen‐binding domains of IgG, CDR1, and CDR2). RESULTS: Elevated CXCL13 levels characterized ESRD (n = 19; [median] 90 pg/ml, P < 0.01) (controls, n = 18; 62 pg/ml). ESRD pTFH frequencies (n = 19; 11.6% [of CD4(+) memory T cells], P < 0.02*, *Bonferroni corrected) (controls, n = 22; 14.9%) and concentrations (n = 19; 0.03 × 10(9)/L, P < 0.02*) (controls, n = 22; 0.07 × 10(9)/L) were reduced. ESRD pTFH were more apoptotic (n = 9; 25.7%, P = 0.04*) (controls, n = 10; 15.9%). SHM did not discriminate between ESRD (n = 10; 7.4%, P = 0.21) and controls (n = 10; 8.4%). CONCLUSIONS: Elevated CXCL13 levels, reduced pTFH levels, and increased pTFH apoptosis suggest that perturbed GC dynamics, and not reduced antibody diversity, underlie the diminished vaccine responses and the compromised humoral immunity in ESRD. However, largely preserved SHM provides a rationale for pursuing vaccination in relation to ESRD. John Wiley and Sons Inc. 2016-05-25 /pmc/articles/PMC4879468/ /pubmed/27957330 http://dx.doi.org/10.1002/iid3.108 Text en © 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Assing, Kristian
Nielsen, Christian
Jakobsen, Marianne
Scholze, Alexandra
Nybo, Mads
Soerensen, Grete
Mortensen, Sussie
Vejen, Knud
Barington, Torben
Bistrup, Claus
Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
title Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
title_full Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
title_fullStr Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
title_full_unstemmed Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
title_short Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
title_sort evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879468/
https://www.ncbi.nlm.nih.gov/pubmed/27957330
http://dx.doi.org/10.1002/iid3.108
work_keys_str_mv AT assingkristian evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT nielsenchristian evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT jakobsenmarianne evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT scholzealexandra evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT nybomads evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT soerensengrete evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT mortensensussie evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT vejenknud evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT baringtontorben evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease
AT bistrupclaus evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease